Why Your Biotech Buys Keep Going Down – And How To Solve The Problem
If you feel like biotech stocks tend to go down right after you buy them, you’re not alone – and today’s article provides some important insights into what’s going on.
Alex Clarke
New Stocks To Watch Involved In Fintech, Disease Prevention, Plant-Based Candy & More
New stocks to watch in 2021.
This “Biotech In Digital Health Clothing” Has The Potential To Become A Powerful Drug Maker
Information collected through genetic testing business has the potential to become a powerful drug developer.
Millionaire-Maker Biotech Penny Stocks
“When it comes to investing in biotech penny stocks, there are some ways to dramatically increase your chances of success and to give yourself a good chance of becoming a millionaire or even a multimillionaire in the process.”
This Pharma Stock Has A Great Record Of Returns In July
Having posted positive returns in July in nine of the last 10 years, with an average July return of 4.8%, the medical devices and health… Read More »This Pharma Stock Has A Great Record Of Returns In July
“Speculative But Promising”: A Newly IPO-ed Biotech With A Very Different Approach To Psychedelics
“New therapies derived from psychedelic compounds…are offering hope, not to mention a slew of opportunities for forward-thinking investors.”
3 Mid-Year Mid-Cap Biotech Picks
“All three picks can be volatile but very tradable and should be considered as long term holds with expectations for growth, positive clinical data or M&A.”
New Stocks To Watch In Tech, Biotech, Homebuilding & More
Tech companies involved in software, AI and e-commerce, and a medical device company that designs innovative injection technologies, are among the new stocks to watch.
A Trio Of Top Biotech Stock Picks
When it comes to the future of the biotech industry, the author of today’s article notes that “the aging population ensures that demand for new… Read More »A Trio Of Top Biotech Stock Picks
With A Potential Blockbuster Drug, And Ripe For Acquisition, This Biotech Stock Could Be A Big Winner
With a potential $5+ billion drug that could ultimately be used against dozens of diseases, the clinical-stage biotech company discussed in today’s article “is a ripe acquisition target, and when that acquisition comes, it will go for a steep price.”